<p>NewAmsterdam Pharma Co（纳斯达克股票代码：NAMS）在过去三个月内被 5 位分析师分析，显示出从看涨到看跌的多样化观点。</p>
<p>下表提供了他们最近评级的简要概览，展示了过去 30 天情绪的变化，并与前几个月进行比较。</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看涨</strong></th>
<th align="right"><strong>稍微看涨</strong></th>
<th align="right"><strong>无所谓</strong></th>
<th align="right"><strong>稍微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>总评级</strong></td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>过去 30 天</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1 个月前</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 个月前</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 个月前</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>分析师通过对 12 个月价格目标的评估提供了更深入的见解，显示出平均目标为 44.8 美元，最高估计为 50.00 美元，最低估计为 37.00 美元。这一上升趋势显而易见，目前的平均值较之前的平均价格目标 39.40 美元增加了 13.71%。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1769018478_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="价格目标图表" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1769018478_0.png"/></p>
<h2>分析分析师评级：详细拆解</h2>
<p>通过审查最近的分析师行动，我们获得了金融专家对 NewAmsterdam Pharma Co 的看法。以下摘要概述了主要分析师、他们最近的评估以及对评级和价格目标的调整。</p>
<table>
<thead>
<tr>
<th>分析师</th>
<th>分析师公司</th>
<th>采取的行动</th>
<th>评级</th>
<th>当前价格目标</th>
<th>之前价格目标</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leonid Timashev</td>
<td>RBC Capital</td>
<td>上调</td>
<td>超越大盘</td>
<td>$47.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>James Condulis</td>
<td>Stifel</td>
<td>上调</td>
<td>买入</td>
<td>$50.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Asad Haider</td>
<td>Goldman Sachs</td>
<td>上调</td>
<td>中性</td>
<td>$37.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Leonid Timashev</td>
<td>RBC Capital</td>
<td>上调</td>
<td>超越大盘</td>
<td>$44.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>上调</td>
<td>买入</td>
<td>$46.00</td>
<td>$40.00</td>
</tr>
</tbody>
</table>
<h3>关键见解：</h3>
<ul>
<li><strong>采取的行动：</strong> 分析师根据不断变化的市场条件和公司表现频繁更新他们的建议。无论是 ‘维持’，‘上调’ 还是 ‘下调’ 他们的立场，反映了他们对 NewAmsterdam Pharma Co 最近发展的反应。这些信息提供了分析师对公司当前状态的快照。</li>
<li><strong>评级：</strong> 分析师揭示了股票的定性评估，从 ‘超越大盘’ 到 ‘表现不佳’。这些评级提供了对 NewAmsterdam Pharma Co 相对于更广泛市场表现预期的见解。</li>
<li><strong>价格目标：</strong> 分析师评估价格目标的动态，为 NewAmsterdam Pharma Co 股票的未来价值提供估计。这一比较揭示了分析师预期随时间变化的趋势。</li>
</ul>
<p>理解这些分析师评估与关键财务指标相结合，可以为 NewAmsterdam Pharma Co 的市场地位提供有价值的见解。保持信息灵通，做出经过深思熟虑的决策，参考我们的评级表。</p>
<p>随时了解 NewAmsterdam Pharma Co 的分析师评级。</p>
<h2>更好地了解 NewAmsterdam Pharma Co</h2>
<p>NewAmsterdam Pharma Co NV 是一家晚期生物制药公司，致力于改善代谢疾病患者的护理，目前批准的疗法尚未足够或耐受性差。其产品 obicetrapib 是一种新一代口服低剂量 CETP 抑制剂，旨在克服当前 LDL-C 降低治疗的局限性。</p>
<h3>分析 NewAmsterdam Pharma Co 的财务表现</h3>
<p><strong>市值分析：</strong> 反映出规模较小，该公司的市值低于行业平均水平。这可能归因于增长预期或运营能力等因素。</p>
<p><strong>收入增长：</strong> NewAmsterdam Pharma Co 在过去 3 个月的收入增长面临挑战。截至 2025 年 9 月 30 日，该公司经历了约 <strong>-98.8%</strong> 的收入下降。这表明公司的顶线收益减少。与竞争对手相比，该公司的增长率低于医疗保健行业的平均水平。</p>
<p><strong>净利润率：</strong> NewAmsterdam Pharma Co 的净利润率低于行业标准，表明在实现强劲盈利能力方面面临困难。净利润率为 <strong>-20691.09%</strong>，该公司可能在有效控制成本方面遇到挑战。</p>
<p><strong>股本回报率（ROE）：</strong> NewAmsterdam Pharma Co 的 ROE 低于行业平均水平，表明在最大化股本回报方面面临挑战。ROE 为 <strong>-9.56%</strong>，该公司可能在实现最佳财务表现方面面临障碍。</p>
<p><strong>资产回报率（ROA）：</strong> NewAmsterdam Pharma Co 的 ROA 低于行业平均水平，表明在有效利用资产方面可能面临挑战。ROA 为 <strong>-8.99%</strong>，该公司可能在实现最佳财务回报方面面临障碍。</p>
<p><strong>债务管理：</strong> NewAmsterdam Pharma Co 的债务与股本比率低于行业平均水平，为 <strong>0.0</strong>，反映出对债务融资的依赖较低，采取了更为保守的财务策略。</p>
<h2>什么是分析师评级？</h2>
<p>评级来自分析师，或在银行和金融系统内的专家，他们为特定股票或定义的行业报告（通常每季度一次）。分析师通常从公司电话会议和会议、财务报表以及与重要内部人士的对话中获取信息，以做出决策。</p>
<p>一些分析师还会提供增长预期、收益和收入等指标的预测，以进一步指导股票。使用分析师评级的投资者应注意，这些专业建议来自人类，可能会出现错误。</p>
<p>本文由 Benzinga 的自动内容引擎生成，并由编辑审核。</p>

NAMS

<p>NewAmsterdam Pharma Co（纳斯达克代码：NAMS）在过去三个月内获得了 5 位分析师的混合评级，平均 12 个月目标价为 44.8 美元，较之前的目标价反映出 13.71% 的增长。分析师们提高了他们的评级，其中 RBC Capital 和 Stifel 的升级尤为显著。然而，该公司面临挑战，包括收入大幅下降 98.8% 和净利润率为-20691.09%。尽管存在这些问题，其债务与股本比率仍然较低，表明其采取了保守的财务策略。该公司专注于开发代谢疾病的治疗方案</p>

<p>NewAmsterdam Pharma Co (NASDAQ: NAMS) has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.</p>
<div class="lb-trans"><p>NewAmsterdam Pharma Co（纳斯达克股票代码：NAMS）在过去三个月内被 5 位分析师分析，显示出从看涨到看跌的多样化观点。</p>
</div><p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<div class="lb-trans"><p>下表提供了他们最近评级的简要概览，展示了过去 30 天情绪的变化，并与前几个月进行比较。</p>
</div><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看涨</strong></th>
<th align="right"><strong>稍微看涨</strong></th>
<th align="right"><strong>无所谓</strong></th>
<th align="right"><strong>稍微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>总评级</strong></td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>过去 30 天</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1 个月前</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 个月前</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 个月前</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
</div><p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $44.8, a high estimate of $50.00, and a low estimate of $37.00. This upward trend is apparent, with the current average reflecting a 13.71% increase from the previous average price target of $39.40.</p>
<div class="lb-trans"><p>分析师通过对 12 个月价格目标的评估提供了更深入的见解，显示出平均目标为 44.8 美元，最高估计为 50.00 美元，最低估计为 37.00 美元。这一上升趋势显而易见，目前的平均值较之前的平均价格目标 39.40 美元增加了 13.71%。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1769018478_0.png" alt="price target chart" original-src="https://www.benzinga.com/files/images/story/2026/1769018478_0.png"/></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<div class="lb-trans"><h2>分析分析师评级：详细拆解</h2>
</div><p>In examining recent analyst actions, we gain insights into how financial experts perceive NewAmsterdam Pharma Co. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<div class="lb-trans"><p>通过审查最近的分析师行动，我们获得了金融专家对 NewAmsterdam Pharma Co 的看法。以下摘要概述了主要分析师、他们最近的评估以及对评级和价格目标的调整。</p>
</div><table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leonid Timashev</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$47.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>James Condulis</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$50.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Asad Haider</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$37.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Leonid Timashev</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$44.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$46.00</td>
<td>$40.00</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>分析师</th>
<th>分析师公司</th>
<th>采取的行动</th>
<th>评级</th>
<th>当前价格目标</th>
<th>之前价格目标</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leonid Timashev</td>
<td>RBC Capital</td>
<td>上调</td>
<td>超越大盘</td>
<td>$47.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>James Condulis</td>
<td>Stifel</td>
<td>上调</td>
<td>买入</td>
<td>$50.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Asad Haider</td>
<td>Goldman Sachs</td>
<td>上调</td>
<td>中性</td>
<td>$37.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Leonid Timashev</td>
<td>RBC Capital</td>
<td>上调</td>
<td>超越大盘</td>
<td>$44.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>上调</td>
<td>买入</td>
<td>$46.00</td>
<td>$40.00</td>
</tr>
</tbody>
</table>
</div><h3>Key Insights:</h3>
<div class="lb-trans"><h3>关键见解：</h3>
</div><ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to NewAmsterdam Pharma Co. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of NewAmsterdam Pharma Co compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of NewAmsterdam Pharma Co's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>采取的行动：</strong> 分析师根据不断变化的市场条件和公司表现频繁更新他们的建议。无论是 ‘维持’，‘上调’ 还是 ‘下调’ 他们的立场，反映了他们对 NewAmsterdam Pharma Co 最近发展的反应。这些信息提供了分析师对公司当前状态的快照。</li>
<li><strong>评级：</strong> 分析师揭示了股票的定性评估，从 ‘超越大盘’ 到 ‘表现不佳’。这些评级提供了对 NewAmsterdam Pharma Co 相对于更广泛市场表现预期的见解。</li>
<li><strong>价格目标：</strong> 分析师评估价格目标的动态，为 NewAmsterdam Pharma Co 股票的未来价值提供估计。这一比较揭示了分析师预期随时间变化的趋势。</li>
</ul>
</div><p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into NewAmsterdam Pharma Co's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<div class="lb-trans"><p>理解这些分析师评估与关键财务指标相结合，可以为 NewAmsterdam Pharma Co 的市场地位提供有价值的见解。保持信息灵通，做出经过深思熟虑的决策，参考我们的评级表。</p>
</div><p>Stay up to date on NewAmsterdam Pharma Co analyst ratings.</p>
<div class="lb-trans"><p>随时了解 NewAmsterdam Pharma Co 的分析师评级。</p>
</div><h2>Get to Know NewAmsterdam Pharma Co Better</h2>
<div class="lb-trans"><h2>更好地了解 NewAmsterdam Pharma Co</h2>
</div><p>NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.</p>
<div class="lb-trans"><p>NewAmsterdam Pharma Co NV 是一家晚期生物制药公司，致力于改善代谢疾病患者的护理，目前批准的疗法尚未足够或耐受性差。其产品 obicetrapib 是一种新一代口服低剂量 CETP 抑制剂，旨在克服当前 LDL-C 降低治疗的局限性。</p>
</div><h3>Breaking Down NewAmsterdam Pharma Co's Financial Performance</h3>
<div class="lb-trans"><h3>分析 NewAmsterdam Pharma Co 的财务表现</h3>
</div><p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<div class="lb-trans"><p><strong>市值分析：</strong> 反映出规模较小，该公司的市值低于行业平均水平。这可能归因于增长预期或运营能力等因素。</p>
</div><p><strong>Revenue Growth:</strong> NewAmsterdam Pharma Co's revenue growth over a period of 3M has faced challenges. As of 30 September, 2025, the company experienced a revenue decline of approximately <strong>-98.8%</strong>. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<div class="lb-trans"><p><strong>收入增长：</strong> NewAmsterdam Pharma Co 在过去 3 个月的收入增长面临挑战。截至 2025 年 9 月 30 日，该公司经历了约 <strong>-98.8%</strong> 的收入下降。这表明公司的顶线收益减少。与竞争对手相比，该公司的增长率低于医疗保健行业的平均水平。</p>
</div><p><strong>Net Margin:</strong> NewAmsterdam Pharma Co's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of <strong>-20691.09%,</strong> the company may encounter challenges in effective cost control.</p>
<div class="lb-trans"><p><strong>净利润率：</strong> NewAmsterdam Pharma Co 的净利润率低于行业标准，表明在实现强劲盈利能力方面面临困难。净利润率为 <strong>-20691.09%</strong>，该公司可能在有效控制成本方面遇到挑战。</p>
</div><p><strong>Return on Equity (ROE):</strong> NewAmsterdam Pharma Co's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>-9.56%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<div class="lb-trans"><p><strong>股本回报率（ROE）：</strong> NewAmsterdam Pharma Co 的 ROE 低于行业平均水平，表明在最大化股本回报方面面临挑战。ROE 为 <strong>-9.56%</strong>，该公司可能在实现最佳财务表现方面面临障碍。</p>
</div><p><strong>Return on Assets (ROA):</strong> NewAmsterdam Pharma Co's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>-8.99%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<div class="lb-trans"><p><strong>资产回报率（ROA）：</strong> NewAmsterdam Pharma Co 的 ROA 低于行业平均水平，表明在有效利用资产方面可能面临挑战。ROA 为 <strong>-8.99%</strong>，该公司可能在实现最佳财务回报方面面临障碍。</p>
</div><p><strong>Debt Management:</strong> NewAmsterdam Pharma Co's debt-to-equity ratio is below the industry average at <strong>0.0</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<div class="lb-trans"><p><strong>债务管理：</strong> NewAmsterdam Pharma Co 的债务与股本比率低于行业平均水平，为 <strong>0.0</strong>，反映出对债务融资的依赖较低，采取了更为保守的财务策略。</p>
</div><h2>What Are Analyst Ratings?</h2>
<div class="lb-trans"><h2>什么是分析师评级？</h2>
</div><p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<div class="lb-trans"><p>评级来自分析师，或在银行和金融系统内的专家，他们为特定股票或定义的行业报告（通常每季度一次）。分析师通常从公司电话会议和会议、财务报表以及与重要内部人士的对话中获取信息，以做出决策。</p>
</div><p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<div class="lb-trans"><p>一些分析师还会提供增长预期、收益和收入等指标的预测，以进一步指导股票。使用分析师评级的投资者应注意，这些专业建议来自人类，可能会出现错误。</p>
</div><p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>
<div class="lb-trans"><p>本文由 Benzinga 的自动内容引擎生成，并由编辑审核。</p>
</div>

评估 NewAmsterdam Pharma 公司：5 位金融分析师的深入见解